Related Experiment Video
Updated: May 12, 2026
07:49
Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Metabolic control in cancer cells.
1Département de physiologie, université de Lausanne, 1005 Lausanne, Switzerland. lluis.fajas@unil.ch
Annales D'Endocrinologie
|April 17, 2013
Summary
Cancer cells exhibit altered metabolism, with cell cycle regulators controlling key pathways like glycolysis and lipid synthesis. The E2F1-CDK4 axis plays a crucial role in cancer cell proliferation and survival.
Area of Science:
- Molecular Biology
- Cancer Metabolism
- Cell Cycle Regulation
Background:
- Cancer cells display significant metabolic reprogramming, including increased glycolysis and biosynthesis.
- Cell cycle regulators are closely linked to metabolic responses and proliferation.
- Dysregulation of metabolic control contributes to tumor development and cancer progression.
Purpose of the Study:
- To review the dual role of cell cycle regulators in controlling proliferation and metabolism in normal and cancer cells.
- To highlight the involvement of the E2F1-CDK4 axis in metabolic regulation.
- To discuss the importance of these metabolic pathways for cancer cell survival.
Main Methods:
- Literature review of cell cycle regulators and cancer metabolism.
- Analysis of the E2F1-CDK4 axis functions.
- Discussion of metabolic pathway regulation in cancer.
Main Results:
- Cell cycle regulators govern both cell proliferation and metabolic pathways.
- The E2F1-CDK4 axis modulates oxidative metabolism, lipid synthesis, and glycolysis.
- These pathways are essential for energy production, biosynthesis, and signaling in cancer cells.
Conclusions:
- Cell cycle regulators are critical controllers of cancer cell metabolism and proliferation.
- Targeting the E2F1-CDK4 axis and associated metabolic pathways may offer therapeutic strategies.
- Understanding metabolic control is key to comprehending cancer progression and survival.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...